Methods in Clinical Cancer Research (MCCR) 2021 | ESMO
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK - ScienceDirect
PDF) Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer
9th Masterclass in Clinical Oncology for Residents of Oncologic Specialties: Workshops and Case Presentations – University of Ioannina
SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
Organization
Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). - Abstract - Europe PMC
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized. - ppt download
Francesco Bertoni has been elected as President of the Lymphoma Project Group of Swiss Group for Clinical Cancer Research
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Home | SAKK
SAKK | BIG against breast cancer
PDF) Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SFSingle agent rituximab in
GitHub - IDSC-io/sakk: Swiss Group for Clinical Cancer Research SAKK
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial - The Lancet
SAKK on Twitter: "Hans Rudolf Keller is the new CEO of SAKK The Board of the Swiss Group for Clinical Cancer Research (SAKK) has elected Hans Ru- dolf Keller as its new
Swiss Group for Clinical Cancer Research (SAKK) – Life Science Zurich Business Network
Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07) - Montemurro - 2018 - Cancer - Wiley Online Library
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. | Semantic Scholar
SCTO Platforms - scto
Indication Lymphome agressif à cellules B récidivant ou ... - CHUV
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer
Tweets with replies by SAKK (@SAKK_ch) / Twitter
SAKK Swiss Group for Clinical Cancer Research Overview | SignalHire Company Profile
